Form 4: Director John F. Milligan Acquires 75,000 Stock Options

John F. Milligan, a Director at 4D Molecular Therapeutics, Inc., has been granted 75,000 stock options as part of the company's non-employee director compensation program.

Summary

• John F. Milligan, a Director of 4D Molecular Therapeutics, Inc. (FDMT), received a grant of 75,000 stock options on June 17, 2026.
• These options were granted automatically under the company's non-employee director compensation program.
• The stock options have an exercise price of $9.42 per share.
• Vesting of the options will occur in stages: 1/3 on June 17, 2027, with the remainder vesting in equal monthly installments until fully vested on June 17, 2029, contingent upon continued service.
• A Change in Control event, as defined by the 2020 Incentive Award Plan, will trigger full vesting of the options.
• Following the grant, Milligan will beneficially own 75,000 shares represented by these options.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral filing, as it represents a standard compensation event for a director rather than a significant financial or strategic development for the company.

Positives

• Director compensation aligns with long-term incentive through stock options.
• The grant of options suggests management confidence in future share price appreciation.
• Vesting schedule encourages continued service and commitment from the director.

Negatives

• The value of the options is contingent on future stock performance and vesting conditions.
• No immediate financial gain for the director; the benefit is potential and future-oriented.

Risks

• The value of the stock options could decrease if the company's stock price falls below the exercise price of $9.42.
• Continued service is required for vesting, meaning the director could forfeit unvested options if service is terminated.
• A Change in Control event, while triggering vesting, could also signal a significant corporate event that may not be positive for all stakeholders.

Future Outlook

The vesting schedule and the provision for full vesting upon a Change in Control suggest management's expectation of continued growth and potential future corporate events. The exercise price of $9.42 indicates a baseline expectation for the stock's future value.

Management Comments

• The stock option grant was automatically granted pursuant to the terms of the Company's non-employee director compensation program.
• The stock options vest and become exercisable with respect to 1/3 of the total shares on June 17, 2027 and in equal monthly installments thereafter, subject to the Reporting Person continuing service to Issuer through each vesting date, until the shares are fully vested on June 17, 2029.
• Additionally, the stock options will vest in full upon the consummation of a Change in Control (as defined in the 2020 Incentive Award Plan).

Industry Context

StockSavvy.ai notes that the issuance of stock options to directors is a common practice in the biotechnology and pharmaceutical sectors, aligning director incentives with shareholder value creation and the long-term success of the company.

Stakeholder Impact

• Shareholders: The grant of options aligns director interests with long-term shareholder value, but the immediate impact is dilution upon exercise, which is standard for equity compensation.
• Employees: This filing does not directly impact employees, but it reflects the company's compensation strategy for its board.
• Management: Reinforces the compensation structure for non-employee directors.

Next Steps

• Director John F. Milligan will continue to serve the company, subject to the vesting schedule.
• The company will continue to operate under its 2020 Incentive Award Plan.
• Potential vesting of options on June 17, 2027, and subsequent monthly vesting periods.

Key Dates

Keywords

Form 4, SEC Filing, Stock Options, Director Compensation, 4D Molecular Therapeutics, FDMT, Beneficial Ownership, Equity Award, Vesting Schedule, Insider Trading